تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $11.6B | $11.0B | $9.9B | $9.3B | $9.9B | $10.8B | $9.4B | $7.7B | $7.5B | $7.7B | $7.5B | $7.5B | $7.4B | $7.1B | $7.4B | $7.5B | $7.4B | $7.5B | $7.2B | $6.7B | $6.3B |
| سود ناخالص | $3.8B | $3.5B | $3.2B | $3.1B | $3.4B | $4.2B | $3.6B | $2.7B | $2.6B | $3.0B | $2.9B | $2.8B | $2.8B | $2.8B | $3.0B | $3.1B | $3.1B | $3.1B | $3.0B | $2.7B | $2.6B |
| حاشیه سود ناخالص % | 33.1% | 31.9% | 32.9% | 33.0% | 34.7% | 39.0% | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | 39.5% | 40.9% | 41.5% | 41.4% | 42.0% | 41.3% | 40.8% | 41.0% |
| سود عملیاتی (EBIT) | $1.6B | $1.6B | $1.3B | $1.3B | $1.4B | $2.4B | $2.0B | $1.2B | $1.1B | $1.2B | $1.3B | $1.4B | $983M | $1.5B | $1.2B | $995M | $1.3B | $1.4B | $1.2B | $1.1B | $1.1B |
| حاشیه سود عملیاتی % | 14.1% | 14.5% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | 20.6% | 16.3% | 13.2% | 17.6% | 18.2% | 16.9% | 16.3% | 18.0% |
| سود خالص | $1.1B | $992M | $871M | $854M | $946M | $2.0B | $1.4B | $858M | $736M | $772M | $645M | $709M | $556M | $849M | $556M | $471M | $721M | $729M | $582M | $340M | $586M |
| حاشیه سود خالص % | 9.2% | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | 11.9% | 7.5% | 6.3% | 9.8% | 9.8% | 8.0% | 5.1% | 9.3% |
| EBITDA | — | $2.2B | $1.9B | $1.3B | $1.8B | $3.2B | $2.4B | $1.6B | $1.4B | $1.5B | $1.5B | $1.6B | $1.3B | $1.8B | $1.5B | $1.3B | $1.6B | $1.6B | $1.5B | $1.3B | $1.3B |
| سود هر سهم (EPS) | $9.45 | $8.78 | $7.71 | $7.56 | $8.02 | $15.59 | $10.52 | $6.31 | $5.29 | $5.51 | $4.54 | $4.89 | $3.83 | $5.55 | $3.47 | $2.94 | $4.07 | $3.88 | $2.97 | $1.74 | $2.94 |
| سهام منتشرشده (میلیون) | — | 113M | 113M | 113M | 118M | 128M | 136M | 136M | 139M | 140M | 142M | 145M | 145M | 153M | 160M | 160M | 177M | 188M | 196M | 195M | 200M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی DGX در دسترس است. /companies/us/DGX
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms